Canola Protein Hydrolysates Show Osteogenic Activity in MC3T3-E1 Cells
Shi D., Fernando IPS., Vahedifar A., Ghosh S., Wu J.
Animal Study, published in J Food Sci (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- J Food Sci (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40260770
- PMCID
- PMC12012869
- DOI
- 10.1111/1750-3841.70210
Abstract (original English)
Osteoporosis, the most prevalent metabolic bone disorder, is a major public health issue. Previous studies indicated the potential of food components in mitigating the risks of osteoporosis. The study aimed to evaluate the potential of canola protein hydrolysates (CPH) on osteoclastogenesis using a pre-osteoblast cell MC3T3-E1. Twenty-two CPHs were prepared by 12 different proteases, either individually or in combination. Three CPHs, prepared by trypsin (CPH-T), Protex 6L (CPH-P), and the combination of Protex 6L and thermoase (CPH-PT) showed promising activity in promoting in vitro bone formation. CPH-T and CPH-PT improved cell proliferation at a concentration of 10 ug/ml, while all three hydrolysates exhibited cytotoxicity at 1000 ug/ml. All three hydrolysates promoted the level of runt-related transcription factor 2 (RUNX2) and type I collagen, and mineralization in osteoblast cells, in a dose-dependent manner. Additionally, these three hydrolysates elevated the osteoprotegerin (OPG) level and reduced the level of receptor activator of nuclear factor kappa-B ligand (RANKL). This study indicated the activity of CPHs in the promotion of bone formation and prevention of osteoclastogenesis, suggesting the potential of CPHs as a promising functional food ingredient against osteoporosis.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.